This page contains brief information about daratumumab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Use in Cancer
Daratumumab is approved to be used alone or with other drugs to treat:
- Multiple myeloma. It is used:
- With bortezomib, melphalan, and prednisone in patients with newly-diagnosed disease or who cannot receive an autologous stem cell transplant.
- With dexamethasone and either bortezomib or lenalidomide in patients who have already received at least one other type of treatment.
- With pomalidomide and dexamethasone in patients who have received at least two other types of treatment including lenalidomide and a proteasome inhibitor.
- Alone in patients who have already received at least three other types of treatment, including a proteasome inhibitor and an immunomodulating agent. It is also used in patients whose disease is refractory to both a proteasome inhibitor and an immunomodulating agent.
Daratumumab is also being studied in the treatment of other types of cancer.
More About Daratumumab
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Daratumumab - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Daratumumab - Check for trials from NCI's list of cancer clinical trials now accepting patients.